{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:20:07Z","timestamp":1788391207280,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurosurgery Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.nec.2026.05.007","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:46:21Z","timestamp":1784864781000},"page":"567-581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuroprotection of the Compressed Spine"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0596-2615","authenticated-orcid":false,"given":"Teleale F.","family":"Gebeyehu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0521-9587","authenticated-orcid":false,"given":"Ashmal S.","family":"Kabani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-6744","authenticated-orcid":false,"given":"Adam","family":"Leibold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-3406","authenticated-orcid":false,"given":"James S.","family":"Harrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3s","key":"10.1016\/j.nec.2026.05.007_bib1","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1093\/neuros\/nyw080","article-title":"Traumatic spinal cord injury-repair and regeneration","volume":"80","author":"Ahuja","year":"2017","journal-title":"Neurosurgery"},{"issue":"5","key":"10.1016\/j.nec.2026.05.007_bib2","doi-asserted-by":"crossref","DOI":"10.3171\/FOC.2008.25.11.E14","article-title":"Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury","volume":"25","author":"Hawryluk","year":"2008","journal-title":"Neurosurg Focus"},{"issue":"4","key":"10.1016\/j.nec.2026.05.007_bib3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.13004\/kjnt.2025.21.e35","article-title":"Potential pharmacologic treatments in spinal cord injury: a narrative review","volume":"21","author":"An","year":"2025","journal-title":"Korean J Neurotrauma"},{"issue":"7","key":"10.1016\/j.nec.2026.05.007_bib4","doi-asserted-by":"crossref","first-page":"914","DOI":"10.5966\/sctm.2015-0381","article-title":"Concise review: bridging the gap: novel neuroregenerative and neuroprotective strategies in spinal cord injury","volume":"5","author":"Ahuja","year":"2016","journal-title":"Stem Cells Transl Med"},{"issue":"5","key":"10.1016\/j.nec.2026.05.007_bib5","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.3390\/molecules20057775","article-title":"Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside","volume":"20","author":"Nagoshi","year":"2015","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.nec.2026.05.007_bib6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/WCO.0000000000001434","article-title":"Riluzole as a pharmacological therapy for spinal cord injury: where does this therapy stand?","volume":"38","author":"Pedro","year":"2025","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"10.1016\/j.nec.2026.05.007_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/1073858412467377","article-title":"Cervical spondylotic myelopathy: the clinical phenomenon and the current pathobiology of an increasingly prevalent and devastating disorder","volume":"19","author":"Kalsi-Ryan","year":"2013","journal-title":"Neuroscientist"},{"issue":"6","key":"10.1016\/j.nec.2026.05.007_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.15643","article-title":"Riluzole for degenerative cervical myelopathy: a secondary analysis of the CSM-PROTECT trial","volume":"7","author":"Fehlings","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"17\u201318","key":"10.1016\/j.nec.2026.05.007_bib9","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1089\/neu.2022.0499","volume":"40","author":"Chow","year":"2023","journal-title":"J Neurotrauma"},{"issue":"2","key":"10.1016\/j.nec.2026.05.007_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1474-4422(20)30407-5","article-title":"Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Fehlings","year":"2021","journal-title":"Lancet Neurol"},{"issue":"17\u201318","key":"10.1016\/j.nec.2026.05.007_bib11","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1089\/neu.2023.0163","article-title":"Safety and efficacy of Riluzole in acute spinal cord injury Study (RISCIS): a Multi-Center, randomized, Placebo-Controlled, double-blinded trial","volume":"40","author":"Fehlings","year":"2023","journal-title":"J Neurotrauma"},{"issue":"1","key":"10.1016\/j.nec.2026.05.007_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/sc.2015.95","article-title":"Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): a randomized, double-blinded, placebo-controlled parallel multi-center trial","volume":"54","author":"Fehlings","year":"2016","journal-title":"Spinal Cord"},{"key":"10.1016\/j.nec.2026.05.007_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105863","article-title":"The sodium-glutamate antagonist riluzole improves outcome after acute spinal cord injury: results from the RISCIS randomised controlled trial analysed using a global statistical analytic technique","volume":"118","author":"Fehlings","year":"2025","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.nec.2026.05.007_bib14","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1007\/s43465-022-00758-6","article-title":"The role of riluzole in acute traumatic cervical spinal cord injury with incomplete neurological deficit: a prospective, randomised controlled study","volume":"56","author":"Kumarasamy","year":"2022","journal-title":"Indian J Orthop"},{"issue":"3","key":"10.1016\/j.nec.2026.05.007_bib15","doi-asserted-by":"crossref","first-page":"656","DOI":"10.4103\/ajns.AJNS_259_16","article-title":"Riluzole can improve sensory and motor function in patients with acute spinal cord injury","volume":"13","author":"Meshkini","year":"2018","journal-title":"Asian J Neurosurg"},{"issue":"9","key":"10.1016\/j.nec.2026.05.007_bib16","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/jcph.1876","article-title":"Longitudinal impact of acute spinal cord injury on clinical pharmacokinetics of riluzole, a potential neuroprotective agent","volume":"61","author":"Nguyen","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.nec.2026.05.007_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/neur.2023.0114","article-title":"Safety and efficacy of Riluzole in traumatic Spinal Cord injury: a systematic review with meta-analyses","volume":"5","author":"Weisbrod","year":"2024","journal-title":"Neurotrauma Rep"},{"issue":"1 Suppl","key":"10.1016\/j.nec.2026.05.007_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3171\/2012.5.AOSPINE12112","article-title":"Pharmacology of riluzole in acute spinal cord injury","volume":"17","author":"Chow","year":"2012","journal-title":"J Neurosurg Spine"},{"issue":"3","key":"10.1016\/j.nec.2026.05.007_bib19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/neu.2013.2969","article-title":"A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury","volume":"31","author":"Grossman","year":"2014","journal-title":"J Neurotrauma"},{"issue":"2","key":"10.1016\/j.nec.2026.05.007_bib20","article-title":"PRISMA2020: an R package and shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst Rev"},{"issue":"2","key":"10.1016\/j.nec.2026.05.007_bib21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/2192568219835516","article-title":"The impact of riluzole on neurobehavioral outcomes in preclinical models of traumatic and nontraumatic spinal cord injury: results from a systematic review of the literature","volume":"10","author":"Tetreault","year":"2020","journal-title":"Glob Spine J"},{"issue":"4","key":"10.1016\/j.nec.2026.05.007_bib22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00003495-199652040-00010","article-title":"Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis","volume":"52","author":"Bryson","year":"1996","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.nec.2026.05.007_bib23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/009127009903900507","article-title":"A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers","volume":"39","author":"Le Liboux","year":"1999","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.nec.2026.05.007_bib24","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/j.1552-4604.1997.tb05630.x","article-title":"Single- and multiple-dose pharmacokinetics of riluzole in white subjects","volume":"37","author":"Le Liboux","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.nec.2026.05.007_bib25","unstructured":"Rorer R-P. Riluzole prescribing information. Collegeville (PA). 1996."},{"issue":"2","key":"10.1016\/j.nec.2026.05.007_bib26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0006-8993(80)90144-4","article-title":"Axonal transport of the cytoskeleton in regenerating motor neurons: constancy and change","volume":"202","author":"Hoffman","year":"1980","journal-title":"Brain Res"},{"issue":"4","key":"10.1016\/j.nec.2026.05.007_bib27","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.bbrc.2005.08.252","article-title":"Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury","volume":"336","author":"Shaw","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"10.1016\/j.nec.2026.05.007_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/sc.2011.184","article-title":"Phosphorylated neurofilament subunit NF-H as a biomarker for evaluating the severity of spinal cord injury patients, a pilot study","volume":"50","author":"Hayakawa","year":"2012","journal-title":"Spinal Cord"},{"issue":"3\u20134","key":"10.1016\/j.nec.2026.05.007_bib29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.wneu.2013.01.007","article-title":"Neurological grading in traumatic spinal cord injury","volume":"82","author":"Kalsi-Ryan","year":"2014","journal-title":"World Neurosurg"},{"issue":"1","key":"10.1016\/j.nec.2026.05.007_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.1984.03340250025015","article-title":"Efficacy of methylprednisolone in acute spinal cord injury","volume":"251","author":"Bracken","year":"1984","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.nec.2026.05.007_bib31","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199005173222001","article-title":"A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study","volume":"322","author":"Bracken","year":"1990","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.nec.2026.05.007_bib32","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/jama.1997.03540440031029","volume":"277","author":"Bracken","year":"1997","journal-title":"JAMA"},{"issue":"1 Suppl","key":"10.1016\/j.nec.2026.05.007_bib33","first-page":"1","article-title":"Methylprednisolone for acute spinal cord injury: an inappropriate standard of care","volume":"93","author":"Hurlbert","year":"2000","journal-title":"J Neurosurg"},{"issue":"Suppl 2","key":"10.1016\/j.nec.2026.05.007_bib34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1227\/NEU.0b013e31827765c6","article-title":"Pharmacological therapy for acute spinal cord injury","volume":"72","author":"Hurlbert","year":"2013","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.nec.2026.05.007_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S031716710000754X","article-title":"Methylprednisolone for acute spinal cord injury: 5-year practice reversal","volume":"35","author":"Hurlbert","year":"2008","journal-title":"Can J Neurol Sci"},{"issue":"9","key":"10.1016\/j.nec.2026.05.007_bib36","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1212\/WNL.0000000000007998","article-title":"High-dose methylprednisolone for acute traumatic spinal cord injury: a meta-analysis","volume":"93","author":"Liu","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.nec.2026.05.007_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e03414","article-title":"The safety and efficacy of steroid treatment for acute spinal cord injury: a systematic review and meta-analysis","volume":"6","author":"Sultan","year":"2020","journal-title":"Heliyon"},{"issue":"4","key":"10.1016\/j.nec.2026.05.007_bib38","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1213\/ANE.0000000000001906","article-title":"Methylprednisolone therapy in acute traumatic Spinal Cord injury: analysis of a regional Spinal Cord model systems database","volume":"124","author":"Sunshine","year":"2017","journal-title":"Anesth Analg"},{"issue":"3 Suppl","key":"10.1016\/j.nec.2026.05.007_bib39","doi-asserted-by":"crossref","first-page":"203s","DOI":"10.1177\/2192568217703085","article-title":"A Clinical Practice Guideline for the management of patients with acute spinal cord injury: recommendations on the use of methylprednisolone sodium succinate","volume":"7","author":"Fehlings","year":"2017","journal-title":"Glob Spine J"},{"issue":"2","key":"10.1016\/j.nec.2026.05.007_bib40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41393-025-01163-0","article-title":"Effect of methylprednisolone in cervical spinal cord injury stratified by injury severity: analysis in 908 patients","volume":"64","author":"Mimura","year":"2026","journal-title":"Spinal Cord"},{"key":"10.1016\/j.nec.2026.05.007_bib41","doi-asserted-by":"crossref","DOI":"10.1177\/21925682261421192","article-title":"Variations in managing acute spinal cord injury in the north American clinical trials network and partner institutes","author":"Gebeyehu","year":"2026","journal-title":"Glob Spine J"},{"issue":"1","key":"10.1016\/j.nec.2026.05.007_bib42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12951-019-0449-3","article-title":"NEP(1-40)-modified human serum albumin nanoparticles enhance the therapeutic effect of methylprednisolone against spinal cord injury","volume":"17","author":"Lin","year":"2019","journal-title":"J Nanobiotechnology"},{"issue":"59","key":"10.1016\/j.nec.2026.05.007_bib43","doi-asserted-by":"crossref","first-page":"99666","DOI":"10.18632\/oncotarget.20649","article-title":"Synthesis of methylprednisolone loaded ibuprofen modified dextran based nanoparticles and their application for drug delivery in acute spinal cord injury","volume":"8","author":"Qi","year":"2017","journal-title":"Oncotarget"},{"issue":"6\u20137","key":"10.1016\/j.nec.2026.05.007_bib44","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1545968318776371","article-title":"First-in-Man intrathecal application of neurite growth-promoting Anti-Nogo-A antibodies in acute spinal cord injury","volume":"32","author":"Kucher","year":"2018","journal-title":"Neurorehabil Neural Repair"},{"issue":"1","key":"10.1016\/j.nec.2026.05.007_bib45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(24)00447-2","article-title":"Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trial","volume":"24","author":"Weidner","year":"2025","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.nec.2026.05.007_bib46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4103\/1673-5374.206633","article-title":"Minocycline targets multiple secondary injury mechanisms in traumatic spinal cord injury","volume":"12","author":"Shultz","year":"2017","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.nec.2026.05.007_bib47","doi-asserted-by":"crossref","DOI":"10.1177\/08977151261432165","article-title":"Efficacy of minocycline in acute traumatic spinal cord injury","author":"Omair","year":"2026","journal-title":"J Neurotrauma"},{"issue":"9","key":"10.1016\/j.nec.2026.05.007_bib48","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.2174\/1570159X23666250313104646","article-title":"Exploring the effectiveness and potential pharmacological mechanism of minocycline for spinal cord injury through meta-analysis and network pharmacology","volume":"23","author":"Hu","year":"2025","journal-title":"Curr Neuropharmacol"},{"issue":"9","key":"10.1016\/j.nec.2026.05.007_bib49","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/BSD.0000000000001695","article-title":"Pharmacologic therapy for spinal cord injury","volume":"37","author":"Sherrod","year":"2024","journal-title":"Clin Spine Surg"},{"key":"10.1016\/j.nec.2026.05.007_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105385","article-title":"Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human Primates","volume":"155","author":"Jacobson","year":"2021","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1016\/j.nec.2026.05.007_bib51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.26503","article-title":"Phase 1 evaluation of elezanumab (Anti-Repulsive guidance molecule A monoclonal antibody) in healthy and multiple sclerosis participants","volume":"93","author":"Kalluri","year":"2023","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.nec.2026.05.007_bib52","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/cpdd.1341","article-title":"Comparability of Elezanumab safety, tolerability, and pharmacokinetics in healthy Japanese, Chinese, and white participants","volume":"13","author":"Kalluri","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"10.1016\/j.nec.2026.05.007_bib53","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ana.27262","article-title":"Randomized, double-blind, placebo-controlled, multiple-dose studies to assess the safety and efficacy of elezanumab when added to standard of care in relapsing and progressive forms of multiple sclerosis","volume":"98","author":"Cree","year":"2025","journal-title":"Ann Neurol"}],"container-title":["Neurosurgery Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104236802600046X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104236802600046X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:03:05Z","timestamp":1788390185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104236802600046X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S104236802600046X"],"URL":"https:\/\/doi.org\/10.1016\/j.nec.2026.05.007","relation":{},"ISSN":["1042-3680"],"issn-type":[{"value":"1042-3680","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroprotection of the Compressed Spine","name":"articletitle","label":"Article Title"},{"value":"Neurosurgery Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nec.2026.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}